Tarsus Pharmaceuticals 3Q 2026: Revenue $194.57M, EPS ($14.4) — 10-Q Summary

What happened

Tarsus Pharmaceuticals reported third-quarter 2026 revenue of $194.57 million, up 63.9% year over year, while its net loss widened to $668.33 million, or $14.4 per diluted share. The company attributed revenue growth to higher XDEMVY sales volume and improved gross-to-net discounts.

Confirmed

Global impact / market context

Higher XDEMVY sales show growing product demand, but the much larger reported loss means revenue growth has not translated into improved bottom-line results. Rising commercial and vendor costs could absorb more cash, while postponed overseas filings may delay opportunities to add sales outside current markets.

Analyst inference

The results combine strong revenue growth with a sharply wider loss, leaving investors to assess whether prescription growth can support better financial performance. The article also describes pipeline trials and deferred international filings, making future research progress and launch timing relevant to the company’s growth outlook.

Analyst inference

What to watch

1. Track XDEMVY prescriptions, refills, and bottles dispensed in later reports to see whether the sales-volume growth continues and supports revenue. Analyst inference
2. Watch for results from the Kore and Calliope programs, expected in the first half of 2027, and for planned Phase 3 trials of IRX-101. Confirmed
3. Look for updates on European and Japanese XDEMVY filings, which Tarsus deferred amid most-favored-nation policy implications, and on commercial and vendor costs. Confirmed

Evidence

• Original source link unavailable